Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of investigational pneumococcal protein-containing vaccine formulations in toddlers
2009-012701-19Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GSK1024850A and 10-valent pneumococcal conjugate vaccine in pneumococcal disease and Haemophilus influenzae disease (5 arms), sponsored by GSK. Primary endpoint: Occurrence of fever greater than 40.0°C after primary vaccination. Started Jul 2009; status: completed.
02
Drugs
GSK1024850A10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal diseaseHaemophilus influenzae disease
Beyond the preview
Go deeper on 2009-012701-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012701-19.